| Title |
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, February 2015
|
| DOI | 10.2147/ceor.s78349 |
| Pubmed ID | |
| Authors |
Josep Darbà, Lisette Kaskens, Francesc Sorio Vilela, Mickael Lothgren |
| Abstract |
The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevention compared with no treatment, generic bisphosphonates, and strontium ranelate in a cohort of osteoporotic postmenopausal women in Spain. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 40% |
| Netherlands | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 3 | 60% |
| Members of the public | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 18% |
| Researcher | 8 | 16% |
| Other | 6 | 12% |
| Student > Master | 5 | 10% |
| Student > Bachelor | 5 | 10% |
| Other | 8 | 16% |
| Unknown | 8 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 47% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Economics, Econometrics and Finance | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Business, Management and Accounting | 1 | 2% |
| Other | 6 | 12% |
| Unknown | 11 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2017.
All research outputs
#7,972,463
of 25,576,801 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#174
of 514 outputs
Outputs of similar age
#101,382
of 362,249 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#3
of 8 outputs
Altmetric has tracked 25,576,801 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 514 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 362,249 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.